[go: up one dir, main page]

MX2009007089A - Preparacion farmaceutica liposomal y metodo para su elaboracion. - Google Patents

Preparacion farmaceutica liposomal y metodo para su elaboracion.

Info

Publication number
MX2009007089A
MX2009007089A MX2009007089A MX2009007089A MX2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A MX 2009007089 A MX2009007089 A MX 2009007089A
Authority
MX
Mexico
Prior art keywords
preparation
liposome formulation
liposome
body temperature
phospholipid
Prior art date
Application number
MX2009007089A
Other languages
English (en)
Inventor
Chunlei Li
Jinxu Wang
Caixia Wang
Yanhui Li
Dongmin Shen
Wenmin Guo
Li Zhang
Lan Zhang
Original Assignee
Shijiazhuang Pharma Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharma Group filed Critical Shijiazhuang Pharma Group
Publication of MX2009007089A publication Critical patent/MX2009007089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una preparación farmacéutica liposomal que contiene un fármaco iónico multivalente, un procedimiento para la preparación de la preparación farmacéutica liposomal, y su uso en el tratamiento de enfermedades, en donde el liposoma tiene un tamaño de aproximadamente 30-80 nm, y la bicapa de fosfolípido tiene un fosfolípido con una Tm más alta que la temperatura corporal, de modo que la temperatura de transición de fase del liposoma es más alta que la temperatura corporal.
MX2009007089A 2006-12-29 2007-12-29 Preparacion farmaceutica liposomal y metodo para su elaboracion. MX2009007089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101023398A CN101209243B (zh) 2006-12-29 2006-12-29 一种脂质体药物及其制备方法
PCT/CN2007/071403 WO2008080367A1 (en) 2006-12-29 2007-12-29 Liposome formulation and process for preparation thereof

Publications (1)

Publication Number Publication Date
MX2009007089A true MX2009007089A (es) 2009-10-08

Family

ID=39588170

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007089A MX2009007089A (es) 2006-12-29 2007-12-29 Preparacion farmaceutica liposomal y metodo para su elaboracion.

Country Status (15)

Country Link
US (2) US20110002977A1 (es)
EP (1) EP2123260B1 (es)
JP (3) JP2010514708A (es)
KR (1) KR101126629B1 (es)
CN (1) CN101209243B (es)
AU (1) AU2007341803B2 (es)
BR (1) BRPI0720733A2 (es)
CA (1) CA2673924C (es)
CO (1) CO6190601A2 (es)
CU (1) CU23980B1 (es)
ES (1) ES2401526T3 (es)
MX (1) MX2009007089A (es)
MY (1) MY150670A (es)
RU (1) RU2494729C2 (es)
WO (1) WO2008080367A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
AU2014200717B2 (en) * 2009-03-30 2016-02-25 Eisai R&D Management Co., Ltd. Liposome composition
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
ES2593027T3 (es) * 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
CN101897667B (zh) * 2009-05-26 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸多柔比星脂质体注射剂及其制备工艺
AU2010272167B2 (en) * 2009-07-14 2016-11-17 Polypid Ltd. Sustained-release drug carrier composition
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
BR112012028787A2 (pt) * 2010-05-10 2017-03-14 J Miller Joseph lipossomos terapêuticos e métodos para produzir e usar os mesmos
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US12097269B2 (en) * 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
KR102186116B1 (ko) * 2012-11-20 2020-12-03 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP6605446B2 (ja) 2013-03-15 2019-11-13 ザ ユニバーシティ オブ ブリティッシュ コロンビア 形質移入用の脂質ナノ粒子および関連方法
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
KR101503492B1 (ko) * 2013-07-03 2015-03-19 전북대학교산학협력단 지질 및 리소좀 효소를 포함하는 리포좀 캡슐 및 그 제조방법
EP3138557B1 (en) * 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and method for producing same
DK3138555T3 (da) * 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
CN111437259A (zh) 2015-11-02 2020-07-24 富士胶片株式会社 包含吉西他滨或其盐的脂质体组合物
ES2952680T3 (es) 2016-04-28 2023-11-03 Eisai R&D Man Co Ltd Eribulina para inhibir el crecimiento tumoral
SG11201906539YA (en) * 2017-01-18 2019-08-27 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
CN108721644B (zh) * 2018-06-05 2021-06-08 常州金远药业制造有限公司 一种紫杉烷类药物脂质体制备方法
JP7364561B2 (ja) 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
EP4098251A4 (en) * 2020-02-10 2024-02-14 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR THE TREATMENT OF BREAST CANCER
WO2021180184A1 (zh) * 2020-03-12 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN115427020A (zh) * 2020-04-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN113876711A (zh) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 一种盐酸阿霉素脂质体的制备工艺
WO2022028566A1 (zh) 2020-08-07 2022-02-10 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体和培门冬酶的用途
KR20230058137A (ko) * 2020-08-27 2023-05-02 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 미토산트론 염산염 리포솜 및 시클로포스파미드, 빈크리스틴, 프레드니손의 용도
CA3202019A1 (en) * 2020-12-15 2022-06-23 Chunlei Li Use of mitoxantrone hydrochloride liposome
WO2022218393A1 (zh) 2021-04-16 2022-10-20 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN115400083A (zh) * 2021-05-28 2022-11-29 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体用于制备治疗晚期实体瘤的药物的用途
CN115770288A (zh) * 2021-09-07 2023-03-10 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
WO2023207931A1 (zh) * 2022-04-26 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途
WO2024017293A1 (zh) 2022-07-20 2024-01-25 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
WO2024046246A1 (zh) 2022-08-29 2024-03-07 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联用卡培他滨治疗鼻咽癌的用途
PL444722A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym
CN119451682A (zh) 2023-06-02 2025-02-14 石药集团中奇制药技术（石家庄）有限公司 包含米托蒽醌脂质体和阿糖胞苷的药物组合物治疗急性髓系白血病的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5169635A (en) * 1989-11-17 1992-12-08 Fuji Photo Film Co., Ltd. Photoresponsive liposome
EP0804925A1 (en) * 1994-03-28 1997-11-05 Daiichi Pharmaceutical Co., Ltd. Liposome with increased retention volume
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
DE69632859T2 (de) * 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
IL142573A0 (en) * 1998-09-16 2002-03-10 Alza Corp Liposome-entrapped topoisomerase inhibitors
DE60014093T2 (de) * 1999-07-16 2005-02-03 Alza Corp., Mountain View Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden
ES2186484B1 (es) * 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
CA2424345A1 (en) 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
CA2506749A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7288396B2 (en) * 2003-09-11 2007-10-30 Kosan Biosciences Incorporated Biosynthetic gene cluster for leptomycins
RU2258530C1 (ru) * 2004-04-27 2005-08-20 Генкин Дмитрий Дмитриевич Способ профилактики и коррекции изменений кожи
UA86063C2 (ru) * 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CN1242740C (zh) * 2004-08-05 2006-02-22 常州太平洋药物研究所有限公司 米托蒽醌或盐酸米托蒽醌脂质体注射剂及其制备工艺
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006298844A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソーム内に医薬化合物を内包するリポソーム含有製剤
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
ES2594368T3 (es) * 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US7703945B2 (en) 2006-06-27 2010-04-27 Cree, Inc. Efficient emitting LED package and method for efficiently emitting light
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
ES2593027T3 (es) * 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
JP5480867B2 (ja) * 2011-10-07 2014-04-23 住友ゴム工業株式会社 空気入りタイヤ

Also Published As

Publication number Publication date
CN101209243B (zh) 2010-12-08
MY150670A (en) 2014-02-28
RU2494729C2 (ru) 2013-10-10
CA2673924A1 (en) 2008-07-10
EP2123260B1 (en) 2013-02-20
KR101126629B1 (ko) 2012-03-26
JP6187961B2 (ja) 2017-08-30
KR20090094043A (ko) 2009-09-02
JP2013177397A (ja) 2013-09-09
CA2673924C (en) 2013-10-01
CN101209243A (zh) 2008-07-02
ES2401526T3 (es) 2013-04-22
CU20090114A7 (es) 2011-02-24
AU2007341803B2 (en) 2011-08-11
US20110002977A1 (en) 2011-01-06
US10028913B2 (en) 2018-07-24
RU2009126983A (ru) 2011-02-10
CO6190601A2 (es) 2010-08-19
AU2007341803A1 (en) 2008-07-10
JP2010514708A (ja) 2010-05-06
WO2008080367A1 (en) 2008-07-10
EP2123260A4 (en) 2010-03-17
AU2007341803A2 (en) 2009-09-03
HK1133398A1 (en) 2010-03-26
EP2123260A1 (en) 2009-11-25
BRPI0720733A2 (pt) 2014-01-07
JP2015180652A (ja) 2015-10-15
US20160235671A1 (en) 2016-08-18
CU23980B1 (es) 2014-01-29

Similar Documents

Publication Publication Date Title
MX2009007089A (es) Preparacion farmaceutica liposomal y metodo para su elaboracion.
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
UA106074C2 (uk) ПОХІДНІ 1H-ІМІДАЗО[4,5-c]ХІНОЛІНОНУ
IL192104A (en) Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation
WO2012091523A3 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
WO2007117509A8 (en) High delivery rates for lipid based drug formulations, and methods of treatment thereof
IL164373A (en) Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer
IL196243A (en) [4,2,1] Triazole [3,4– a Pyridine Derivatives
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
WO2008064192A3 (en) Modified release analgesic suspensions
WO2007107305A3 (en) Treatment of triple receptor negative breast cancer
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
NZ579881A (en) Transpulmonary liposome for controlling drug arrival
IL197575A (en) A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells
IL223770A (en) History 7,6-Dihydro-5 h- Benzo [7] Enolene, Methods of Manufacturing, Pharmaceutical Preparations Containing and Using Them to Make Medical Products
WO2010017325A3 (en) Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
IL205290A (en) A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs
PL1880718T3 (pl) Preparat farmaceutyczny do podawania doustnego o kontrolowanym uwalnianiu w jelicie cienkim i sposób jego wytwarzania
WO2008051527A3 (en) Sustained release of agents for localized pain management
Siddiqui et al. Writing emails as part of sleepwalking after increase in Zolpidem
BRPI1009003A2 (pt) "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"
CN101547703A (zh) S-亚硝基硫醇化合物和相关衍生物
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы

Legal Events

Date Code Title Description
FG Grant or registration